All In Biotech

Drug Trial Radar · NCT07767474

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

343

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Oct 28, 2029

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Antares Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ATX-898-101 is a phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetic, and preliminary efficacy of ATX-898 as monotherapy and in combination with anti-neoplastic agents in selected solid tumors. This study consists of 2 parts. Part 1 evaluates ATX-898 as monotherapy and Part 2 evaluates ATX-898 in combination with anti-neoplastic agents of interest. Both parts will consists of a dose escalation portion and a dose expansion portion.

Conditions

  • Advanced Solid Tumors

Interventions

  • ATX-898Drug

    Doses defined per protocol

  • ATX-898Drug

    RDE

  • ATX-898Drug

    RDE

  • ATX-898Drug

    RDE

  • ATX-898Drug

    Doses defined per protocol

  • ATX-898, fulvestrant, ribociclibDrug

    ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol

  • ATX-898, fulvestrant, ribociclibDrug

    ATX-898 at RDE, Fulvestrant and abemaciclib: doses defined per protocol

  • ATX-898, fulvestrant, ribociclibDrug

    Doses defined per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1a monotherapy dose escalation - Occurrence of Dose limiting toxicities (DLTs)Time frame: 12 months
  2. Part 1a monotherapy dose escalation - Maximally tolerated/tested dose (MTD)Time frame: 12 months
  3. Part 1a monotherapy dose escalation - Recommended dose for expansion (RDE)Time frame: 12 months
  4. Part 1a monotherapy dose escalation - Treatment emergent adverse events (TEAEs)Time frame: 12 months
  5. Part 1b monotherapy dose expansion - Objective Response Rate (ORR)Time frame: 24 months
  6. Part 2a combination dose escalation - Occurrence of Dose limiting toxicities (DLTs)Time frame: 18 months
  7. Part 2a combination dose escalation - Maximally tolerated/tested dose (MTD)Time frame: 18 months
  8. Part 2a combination dose escalation - Recommended dose for expansion (RDE)Time frame: 18 months
  9. Part 2a combination dose escalation - Treatment emergent adverse events (TEAEs)Time frame: 18 months
  10. Part 2b combination dose expansion - Objective Response Rate (ORR)Time frame: 36 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • START Dallas Fort Worth Cancer Center

    Fort Worth, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START San Antonio Cancer Center

    San Antonio, Texas · Recruiting

  • START Mountain Region Cancer Center

    West Valley City, Utah · Recruiting

  • NEXT Virginia Cancer Center- Merrifield Tech Center

    Fairfax, Virginia · Recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.